Management of Aromatase Inhibitor–Induced Arthralgia
790 Commissioners Road East, London, ON N6A 4L6, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2010, 17(1), 87-90; https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17i1.474
Submission received: 7 November 2009
/
Revised: 8 December 2009
/
Accepted: 2 January 2010
/
Published: 1 February 2010
Abstract
Aromatase inhibitors (AIS) are commonly used as adjuvant treatment in postmenopausal women with hormone receptor–positive early breast cancer. With both steroidal and nonsteroidal AIS, AI-induced arthralgia is frequently observed. The mechanism of AI-induced arthralgia remains unknown, and the data available from clinical trails using AIS are limited. We review the pertinent information from a clinical perspective, including an algorithm to treat AI-induced arthralgia.
Keywords:
aromatase inhibitors; arthritis; arthralgia; breast cancer
Share and Cite
MDPI and ACS Style
Younus, J.; Kligman, L. Management of Aromatase Inhibitor–Induced Arthralgia. Curr. Oncol. 2010, 17, 87-90. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17i1.474
AMA Style
Younus J, Kligman L. Management of Aromatase Inhibitor–Induced Arthralgia. Current Oncology. 2010; 17(1):87-90. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17i1.474
Chicago/Turabian StyleYounus, J., and L. Kligman. 2010. "Management of Aromatase Inhibitor–Induced Arthralgia" Current Oncology 17, no. 1: 87-90. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17i1.474
